Digital Learning
Scientific Posters
WRIB, 2025
Method Qualification For Immunophenotyping Of Cd137+ T Cell Subsets In Human Whole Blood By Flow Cytometry Using Contrived Samples
WRIB, 2025
Comparison Of Different Assay Kits For Dog Serum Parathyroid Hormone (PTH) Measurement
WRIB, 2025
Method Validation Of Classical And Alternative Pathway Complement Activity In Human Serum
WRIB, 2025
A Quantitative Analysis Method For Intracellular Proteins (IKAROS/AIOLOS) By Flow Cytometry To Support Pharmacodynamic Studies Of Targeted Protein Degraders
WRIB, 2025
LCMS Bioanalysis Of Oligonucleotides: Optimization Of Alkylamines And Fluorinated Alcohols As Solvent Modifiers
SOT, 2025
Validation of the Flow Cytometry Based Pig-a Gene Mutation Assay in Rats
SOT, 2025
A Retrospective Analysis of the Potential Associated Factors of Procedure-Related Findings in Intrathecal Injection Studies
SOT, 2025
Case Study-Strategy of Follow-up Assays in Genotoxicity
SOT, 2025
Comparison of Systemic Exposure in Pregnant and Non-Pregnant Sprague-Dawley Rats
SOT, 2025
Early siRNA Formulation Screening Using Lumbar Intrathecal Infusion via Cannulation vs. Free-Hand Method – A Comparison for Preliminary Toxicity Detection Using Behavioral Tests and Tissue Distributions
SOT, 2025
Establishing the Preclinical Immunotoxicity Reference Based on Immunophenotyping Data in Bama Minipigs
SOT, 2025
Evaluation of the Impact of the Use of Slide Imaging in the Histopathological Evaluation of Toxicology Studies
SOT, 2025
Method Validation for the Reactive Oxygen Species (ROS) Assay for Photoreactivity
SOT, 2025
Spontaneous Lesions Associated with Test Article-Unrelated Deaths in Repeated Dose Mouse Studies
SOT, 2025
Spontaneous Ocular Lesions Observed in Laboratory Animals
SOT, 2025
Validation of Fluorescence In Situ Hybridization Method in Mouse – With a Novel Staining Strategy
White Papers
Optimizing DART Assessments for Regulatory Success & Emerging Modalities
Detect and Characterize In Vitro PCCs of Non-Cleavable ADCs Using a New LC-HRMS Method
Pharmacokinetic Bioanalysis Strategies for Antibody-Drug Conjugates (ADCs)
Based on LC-MS
The BAMA MINIPIG in Toxicology
Bridging Preclinical and Clinical Assays for Biologics Development –Challenges and Considerations for Phase I Trials
Comparison Between Magnetic Bead and Membrane Immunoaffinity Purification Methods for the Measurement of Monoclonal Antibody in Rat Serum
Internal Standard (IS) Variation Case Studies: Emerging From Three Common IS Challenges
Metabolite Identification (MetID): A Critical Step in Drug Discovery and Development
ICH M10 Guidance: Harmonization and Modification to Bioanalytical Method Variation
The 2019 FDA Guidance’s Implications for Immunogenicity Assessment
Developing a Convenient In Vitro Method for Predicting Metabolism and Disposition of Acrylamide Covalent Drugs in Humans
Webinars
Upcoming Webinars
in association with
Peptide Therapeutics: Navigating Development with DMPK & Toxicology
Wednesday, July 9, 2025
07:00 [PST] 10:00 [EST] 15:00 [GMT]
Peptide therapeutics offer immense potential but present complex development challenges, particularly in oral formats. This expert-led presentation explores how integrated DMPK, bioanalytical, and toxicology strategies can address barriers to absorption, stability, and safety. Focusing on practical case examples and proven approaches; it highlights how thoughtful study design and cross-functional expertise can streamline development and reduce risk from early studies through clinical advancement.
Panel Discussion: Advancing Bioanalytical Method Development and Validation for Small Molecules in a Changing Regulatory Landscape
This session covers the current landscape of bioanalytical method development and validation for small molecules, including method development strategies, emerging technologies and validation best practices.
in association with
Past Webinars
Advancing In Vitro Metabolic Models and Metabolite Identification for Oligonucleotide Therapeutics
Oligonucleotide DMPK Research Strategy & In Vitro Metabolism Models
Optimizing DMPK Strategy for Peptide Drugs
Nervous System (CNS) Drug Delivery Techniques in Large Animals (Non-Rodents) Enhancing DMPK Research for Oligonucleotide Drugs
Discovery, Characterization, and Manufacture of Peptide Radiopharmaceuticals
Integrated bioanalytical strategy for LNP-mRNA products
Facilitating ADC Preclinical DMPK Research with An Integrated Bioanalysis Platform
Facilitating ADC Preclinical DMPK Research with An Integrated Bioanalysis Platform
Challenges and solutions in bioanalysis for oligonucleotide drugs
Overcoming Challenges in Precise Structural Identification of Target Metabolites
DMPK Strategies for Oligonucleotide Therapeutics
Challenges and solutions in bioanalysis for oligonucleotide drugs
DMPK Strategies for Successful Clinical Translation
Hot Topics and Challenges in Drug Development
The Strategies and Methods of in-vitro ADME Characterizations of ADCs
ICP-MS
DMPK Addressing Safety Testing of Drug Metabolites (MIST) in Drug Development
Preclinical Oligonucleotide Drug Development: Insight from DMPK
Expediting Biologics Drug Development: Strategies to Accelerate Preclinical Development Timelines
DMPK Optimization of Proteolysis-Targeting Chimeras
DPMK Strategies in the Preclinical Development of Antibody-Drug Conjugates
Brochures
Opthamology Services Brochure
IND, Enabled
Bioanalytical Services
Proteolysis Targeting Chimera
Peptide
Oligonucleotide Drugs
Peptide-Drug Conjugate
Safety Assessment Services
Antibody Drug Conjugate
Service Catalog
Drug Metabolism and Pharmacokinetics
Presentations
Check out our 15-minute presentation on the revolutionary impact of ADCs in targeted cancer therapy. Detailing their journey from conception to becoming a leading treatment modality, we highlight the significant bioanalytical challenges and regulatory milestones that shape ADC development.
What you will learn:
- The components of ADCs and their roles in targeting and killing tumor cells
- Bioanalytical details on PK, PD, immunogenicity, receptor occupancy and immunotoxicity studies
- Analytical platforms and techniques
- Challenges in ADC bioanalysis
- Guidelines and strategies for biomarker bioanalysis
Nonclinical Safety Evaluations of ADC Drugs
Animal Disease Models in Ocular Drug Development
Cost-effective In Vitro Methods for Evaluating the DDI Potential in Drug Discovery
Is your Drug Ready for an IND?
Maximizing Outcomes Through Multi-Site Study Collaboration
Development, Comparison of Quantitative Analytical Methods to Evaluate Plasma Antibody-Drug-Conjugates
Smart Strategies of ADME-PK for Large Molecules
In Vitro DDI Considerations for New Modalities
Integrated Bioanalysis and Biotransformation Strategies for Antibody-Drug Conjugates